title: [Changes of plasma fibrinolysis system and the effect of captopril in high altitude pulmonary edema].
abstract: OBJECTIVE
  To investigate the changes of plasma fibrinolysis system and the effect of captopril in patients with high altitude pulmonary edema.
  
  
  METHODS
  The plasma levels of tissue plasminogen activator (tPA) and plasminogen activator inhibitor-1 (PAI-1) were measured before and after treatment in the captopril-group (group A, 35 cases) and the routine-group (group B, 37 cases) of patients with HAPE, while 20 healthy volunteers served as the control (group C).
  
  
  RESULTS
  The plasma level of tPA was (0.40 +/- 0.14) x 10(3) IU/L in group A vs (0.39 +/- 0.19) x 10(3) IU/L in group B before treatment, and (0.58 +/- 0.13) x 10(3) IU/L vs (0.49 +/- 0.16) x 10(3) IU/L after treatment, and (0.59 +/- 0.17) x 10(3) IU/L in group C. The differences were significant both before and after treatment between group A and group B (P < 0.01, P < 0.05). While PAI-1 was (6.6 +/- 1.8) x 10(3) AU/L in group A vs (6.6 +/- 1.6) x 10(3) AU/L in group B before treatment, and (4.9 +/- 1.5) x 10(3) AU/L vs (5.8 +/- 1.7) x 10(3) AU/L after treatment, and (4.9 +/- 1.3) x 10(3) AU/L in group C. The differences were significant both before and after treatment between group A and group B (P < 0.01, P < 0.05).
  
  
  CONCLUSIONS
  Patients with HAPE may present a disturbance of the fibrinolysis system, which could be reversed by captopril.
authors.affiliation: Department of Internal Medicine, 41st Hospital of People's Liberation Army, Shannan, Tibet 856100, China.
authors.forename: Jun
authors.initials: J
authors.lastname: Yu
authors.forename: Dang-sheng
authors.initials: DS
authors.lastname: Li
authors.forename: Ying-quan
authors.initials: YQ
authors.lastname: Lei
authors.forename: Huan-ling
authors.initials: HL
authors.lastname: Ba
authors.forename: Zhong-ming
authors.initials: ZM
authors.lastname: Fu
authors.forename: Shi-dong
authors.initials: SD
authors.lastname: Li
authors.forename: Tong-chuan
authors.initials: TC
authors.lastname: Hou
authors.forename: Chuan-li
authors.initials: CL
authors.lastname: Peng
mesh_terms: D000293:Adolescent; D000328:Adult; D000531:Altitude; D002216:Captopril / Q000627:therapeutic use*; D005260:Female; D005342:Fibrinolysis; D006801:Humans; D008297:Male; D017395:Plasminogen Activator Inhibitor 1 / Q000097:blood; D011654:Pulmonary Edema / Q000097:blood / Q000188:drug therapy*; D010959:Tissue Plasminogen Activator / Q000097:blood
chemical_list: D017395:Plasminogen Activator Inhibitor 1; D002216:Captopril; D010959:Tissue Plasminogen Activator